Citations 2
Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference
Kloske, Courtney M. , Batista, André F., Carrillo, María C. , Chakrabarty, Paramita , Chen, Xiaoying , Craft, Suzanne , Mesquita, Sandro Dá , Devanand, Davangere P. , Durán‐Laforet, Violeta , Fitzgerald‐Bocarsly, Patricia , Hong, Soyon , Jackvony, Stephanie , Lai, Laijun , Liddelow, Shane A. , Martín‐Peña, Alfonso , Orr, Anna G. , Quintana, Francisco José López , Ramey, G. , Sexton, Claire E. , Torrellas, Jose, Tsai, Andy P. , Wharton, Whitney , Da Mesquita, Sandro , Mahinrad, Simin , Barnum, Christopher J. , Bradshaw, Elizabeth M. , Butts, Brittany , Dabin, Luke Child , Elyaman, Wassim , Evans, Elizabeth E. , Foley, Kate E. , Harms, Ashley S. , Heneka, Michael T. , Huang, Yu‐Wen Alvin , Le Guen, Yann , Lemere, Cynthia Ann , Quintana, Francisco J., Rexach, Jessica E. , Rizzo, Stacey J. Sukoff , Tang, Alice , Olst, Lynn van , Walker, Keenan A. , Tansey, Malú G. , Wilcock, Donna M.
Alzheimer's & Dementia | December 18, 2024 | Volume: 21 | Issue: 1 | Pages: No page available
Abstract The immune system is a key player in the onset and progression of neurodegenerative disorders. While brain resident immune cell‐mediated neuroinflammation and peripheral immune cell (eg, T cell) infiltration into the brain have been shown to significantly contribute to Alzheimer's disease (AD) pathology, the nature and extent of immune responses in the brain in the context of AD and related dementias (ADRD) remain unclear. Furthermore, the roles of the peripheral immune system in driving ADRD pathology remain incompletely elucidated. In March of 2023, the Alzheimer's Association convened the Alzheimer's Association International Conference (AAIC), Advancements: Immunity, to discuss the roles of the immune system in ADRD. A wide range of topics were discussed, such as animal models that replicate human pathology, immune‐related biomarkers and clinical trials, and lessons from other fields describing immune responses in neurodegeneration. This manuscript presents highlights from the conference and outlines avenues for future research on the roles of immunity in neurodegenerative disorders. Highlights The immune system plays a central role in the pathogenesis of Alzheimer's disease. The immune system exerts numerous effects throughout the brain on amyloid‐beta, tau, and other pathways. The 2023 AAIC, Advancements: Immunity, encouraged discussions and collaborations on understanding the role of the immune system.
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, Howard , Cummings, Jeffrey L., Boxer, Adam L., Staffaroni, Adam M. , Knopman, David S., Territo, Paul R. , Arnold, Steven E. , Boeve, Bradley F., Dacks, Penny A. , Diaz, Kristophe , Ewen, Colin, González, María Isabel , Harris, Glenn A., Hoffman, Beth J., Martinez, Terina N. , Nisenbaum, Laura K., Palma, Jose‐Alberto , Quintana, Melanie , Rabinovici, Gil D. , Rohrer, Jonathan D. , Rosen, Howard J., Troyer, Matthew D. , Kim, Doo Yeon , Tanzi, Rudolph E. , Zetterberg, Henrik, Ziogas, Nick, May, Patrick C. , Rommel, Amy, Feldman, Howard H , Palma, Jose-Alberto , Rohrer, Jonathan D , Rabinovici, Gil D , Dacks, Penny , Boxer, Adam L. , Knopman, David S. , Rizzo, Stacey J. Sukoff , Ballard, Clive , Beher, Dirk , Boeve, Bradley F. , Fiske, Brian , McDade, Eric , Zetterberg, Henrik
Alzheimer's & Dementia | September 24, 2024 | Volume: 20 | Issue: 11 | Pages: 8129-8152
AbstractThe tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early‐phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early‐phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need.Highlights Experts provided a framework to translate therapeutics (discovery to clinical trials). Experts focused on the “5 Rights” (target, drug, biomarker, participants, trial). Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics) Tau therapeutics are being tested in Alzheimer's disease; primary tauopathies have a large unmet need.